Injections of PYY(3�36) have shown positive effects on appetite regulation. With nearly 400 million adults worldwide considered obese, these positive effects have sparked an increased interest in PYY research, including release profiles, receptor targets, and medicinal applications. A major area of interest is oral delivery of PYY(3�36) that can display clinically relevant outcomes related to weight loss in what would be a highly patient compliant route. The vitamin B12 pathway has already been successfully used for oral delivery of other peptides including erythropoietin and insulin. We present the overexpression and isolation of a recombinant PYY(3�36) as well as the synthesis, purification, and characterization of a B12�PYY(3�36) conjugate for oral delivery in in vivo studies.

Overexpression, isolation, and oral delivery of the appetite suppressant PYY(3–36)

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.